Analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to post earnings per share of ($1.20) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for OncoSec Medical’s earnings. The company is scheduled to issue its next quarterly earnings report on Friday, September 13th.
On average, analysts expect that OncoSec Medical will report full year earnings of ($5.27) per share for the current fiscal year. For the next financial year, analysts forecast that the company will report earnings of ($4.20) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for OncoSec Medical.
ONCS has been the topic of a number of recent research reports. Maxim Group set a $6.00 target price on OncoSec Medical and gave the stock a “buy” rating in a research note on Wednesday, July 31st. ValuEngine upgraded OncoSec Medical from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research lowered OncoSec Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. OncoSec Medical presently has an average rating of “Buy” and a consensus target price of $19.75.
Shares of NASDAQ ONCS traded up $0.06 during trading hours on Monday, reaching $2.00. 48,172 shares of the stock were exchanged, compared to its average volume of 118,794. OncoSec Medical has a 52 week low of $1.80 and a 52 week high of $19.60. The stock’s fifty day simple moving average is $2.24 and its 200 day simple moving average is $1.42.
In related news, Director Alpha Holdings, Inc. purchased 90,000 shares of OncoSec Medical stock in a transaction that occurred on Tuesday, July 16th. The shares were acquired at an average price of $2.30 per share, with a total value of $207,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 5.40% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new stake in OncoSec Medical in the second quarter valued at approximately $33,000. Worth Venture Partners LLC bought a new position in shares of OncoSec Medical during the second quarter worth approximately $99,000. Private Advisor Group LLC bought a new position in shares of OncoSec Medical during the second quarter worth approximately $27,000. JPMorgan Chase & Co. bought a new position in shares of OncoSec Medical during the second quarter worth approximately $46,000. Finally, Geode Capital Management LLC increased its stake in shares of OncoSec Medical by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 163,405 shares during the period. 23.56% of the stock is currently owned by institutional investors and hedge funds.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Featured Story: How to Use the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.